Invitrocue and Genecast form Partnership to create Real-time Personalized Adaptive Care for Cancer Patients
“Combining Onco-PDO and Ultrasenstive ADPS delivers unmatched Precision, Ultra-sensitive Detection, and is Fast and Accessible"”
Coming Soon: Smart Treatments That Adapt in Real Time to Beat Cancer
Singapore, June 17, 2025, 06:00 AM +08 — Invitrocue and Genecast are thrilled to unveil a transformative advancement in cancer care: the Real-Time Patient Adaptive Cancer Care Program enabling functional cure, launching within months in select countries. This pioneering partnership merges Invitrocue’s Onco-PDO platform with Genecast’s ultrasensitive ADPS technology to deliver personalized treatments that dynamically adapt to evolving cancers, striving for superior outcomes and potential cures.
A New Era in Cancer Treatment
Conventional cancer treatments often involve trial-and-error, with results delayed by months of imaging or blood tests, risking disease progression. The Invitrocue-Genecast solution revolutionizes this approach. Invitrocue’s Onco-PDO platform uses patient-derived organoids to pinpoint the most effective drugs for each patient’s cancer before treatment starts. Genecast’s ADPS (Allele Discrimination Priming System) tracks treatment response, drug resistance, and early relapse in real time—daily or weekly—via a simple blood test, enabling doctors to adjust therapies swiftly for optimal results.
Why This Matters
- Unmatched Precision: Onco-PDO provides real-world tested drug & dosing data with exceptional accuracy for all solid tumors, including rare cancers, empowering doctors in Germany, Singapore, Hong Kong, and Thailand to select the right drugs today. Invitrocue is preparing to expand access to the USA, South Korea, and beyond.
- Ultra-Sensitive Detection: ADPS detects cancer signals at 0.001%-0.01% MAF, representing 100X increased sensitivity versus current standard methods. Clinically validated by peer-reviewed studies with institutions like Harvard Medical School and Samsung Medical Center, it identifies resistance or relapse early, offering patients in these markets a critical edge. This service will be available wherever Onco-PDO is offered.
- Fast and Accessible: Delivering results in within 1-2 days without specialized equipment, and with Onco-PDO already covered by insurance in Germany, Onco-PDO and ADPS are cost-effective and clinic-ready in advanced healthcare systems like Germany and Thailand, with the USA, South Korea, Japan, and Singapore to follow. The program reduces diagnostic costs compared to traditional NGS-based monitoring methods, which can exceed $3,000 per run.
Real Stories, Real Hope
Picture a lung cancer patient. Instead of enduring months of uncertainty, their doctor uses Onco-PDO to choose the best drugs upfront. ADPS monitors their progress weekly, detecting resistance early and tweaking treatment to halt cancer’s advance. After months with no detectable cancer, they’re on the path to remission—a future this program makes possible for countless patients.
What’s Next
The Real-Time Patient Adaptive Cancer Care Program will launch in months in top medical centers across Germany and Thailand, with expansion planned for the USA, South Korea, Japan, Singapore and other regions. To secure broader global insurance coverage, large-scale prospective clinical studies are being pursued with leading cancer centers in the EU, Asia, and USA, in collaboration with Xylonix, which envisioned this program and united Invitrocue and Genecast. Backed by robust clinical validation and multinational approvals, this partnership is set to redefine cancer care worldwide.
A New Level of Efficiency for Cancer Research
For pharmaceutical companies, Genecast’s ADPS technology opens a groundbreaking era in cancer research. By slashing the time needed to observe treatment responses—down to days instead of months—ADPS delivers high-definition data on most known cancer driver mutations. This unprecedented insight can accelerate clinical drug development, uncover new therapeutic targets, and redefine how we understand cancer’s evolution, making it a game-changer for the industry.
Quotes
- “Invitrocue’s Onco-PDO equips doctors with precise drug selection data from the outset, transforming patient outcomes in Singapore, Germany and beyond,” said Dr. Steven Fang of Invitrocue.
- “Genecast’s ADPS delivers unmatched sensitivity, keeping us ahead of cancer’s constant evolution, and at affordable pricing for weekly cancer monitoring” said Dr. Byung Chul Lee of Genecast.
- “This partnership democratizes precision cancer care, making it affordable and accessible with 100-fold more sensitive, real-time monitoring” said Dr. Jinhyuk Fred Chung of Xylonix, “It will be especially effective in combating fast-evolving aggressive cancers like the recently emerging turbocancers by allowing real-time treatment adjustments”.
For partnership opportunities, contact:
Xylonix Business Development
Email: contact@xylonix.io
Website: xylonix.io
About Invitrocue
Invitrocue transforms bioanalytics with its Onco-PDO platform, providing real-world drug selection data to guide cancer treatment decisions.
About Genecast
Genecast pioneers ultrasensitive cancer detection with its ADPS technology, enabling real-time monitoring and personalized treatment adjustments.
About Xylonix
Xylonix drives innovation by uniting cutting-edge technologies with fast go-to-market strategies. Spearheading the science behind the Real-Time Patient Adaptive Cancer Care Program, it also focuses on products for post-pandemic oncology, chronic inflammations, immune deficiency, and respiratory infections for bringing real improvements in patient survival and quality of life.
For more information, please contact: contact@xylonix.io
Media Officer: Gregory Irving – g.irving@xylonix.io